简体
简体中文
繁體中文

Immutep IMMP 深 沪

等待开盘 11-16 09:30:00 美东时间

3.48

-0.175

-4.79%

华盛通华盛通
立即下载
  • 最 高3.76
  • 今 开3.65
  • 成交量 1.48万股
  • 最 低 3.4221
  • 昨 收 3.655
  • 总市值 2564.95万
  • 52周最高 70.598
  • 市盈率 静 --
  • 换手率 0.20%
  • 52周最低 2.66
  • 委 比 12.28%
  • 总股本 737.06万
  • 历史最高 159.00
  • 量 比 0.20
  • 振 幅 9.24%
  • 历史最低 2.66
  • 每 手 1
  • 风险率 21.70%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • IMMP收跌4.79%,成交额5.24万美元

    11月14日,IMMP(IMMP)收跌4.79%,报3.48美元,成交额5.24万美元,市值2564.25万美元。 行情数据 • 开盘价:3.65美元 • 最高...

    11-14 08:40

  • Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial

    Immutep Limited (NASDAQ:IMMP) on Tuesday announced that investigators in its Phase 2 trial observed promising preliminary long-term outcomes for its lead candidate, alongside securing a new U.S. patent that shields its combination therapies through 2038. Clinical investigators evaluated eftilagimod ...

    11-12 00:27

  • IMMP收涨24.16%,成交额30.71万美元

    11月7日,IMMP(IMMP)收涨24.16%,报3.34美元,成交额30.71万美元,市值2461.17万美元。 行情数据 • 开盘价:2.69美元 • 最...

    11-07 08:38

  • Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

    Immutep Limited announced that data from two clinical trials of its MHC Class II agonist, eftilagimod alfa (efti), will be presented at two international congresses in November and December 2026. At the CTOS 2026 Annual Meeting in Seoul, survival data from the EFTISARC-NEO Phase II trial evaluating efti in combination with KEYTRUDA and radiotherapy for resectable soft tissue sarcoma will be presented. At the ESMO Immuno-Oncology & Advanced Therap...

    11-05 13:00

  • IMMP收跌2.44%,成交额3.69万美元

    11月4日,IMMP(IMMP)收跌2.44%,报3美元,成交额3.69万美元,市值2204.2万美元。 行情数据 • 开盘价:3.03美元 • 最高价:3....

    11-04 08:43

  • Immutep Quarterly Activities Report Q1 FY27

    Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...

    10-29 12:00

  • Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program

    Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Im...

    10-28 20:02

  • Immutep Receives A$2.16 million French R&D Tax Incentive

    Immutep Limited received a €1.36 million cash payment from the French Government under its CIR research tax incentive program for eligible R&D activities in 2025. This follows an A$0.86 million rebate from Australia and eligibility for Germany’s R&D tax incentive. The non-dilutive funding will support R&D for eftilagimod alfa (efti) and IMP761. Immutep’s cash reach extends into the first half of 2028.

    10-28 12:00

  • IMMP收涨1.61%,成交额4.26万美元

    10月28日,IMMP(IMMP)收涨1.61%,报3.15美元,成交额4.26万美元,市值2321.06万美元。 行情数据 • 开盘价:3.1美元 • 最高价...

    10-28 07:44

  • Immutep Files 2026 Form 20-F, Confirms Accelerated Filer Status

    Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited has filed...

    10-26 05:55